Given that GLP-1 medications are typically administered via peripheral injection in clinical settings, and acknowledging the capability of the GLP-1RAs exendin-4 to traverse the BBB, this study employed peripheral GLP-1 interventions to observe their effects on PD mice. Here, GLP1R is linked to Parkinson disease.